अApnaFunda
Menu

PROCTER AND GAMBLE HEALTH LTD (PGHL)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.77 / 100
Profitability 91Growth 40Balance sheet 100
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.45 / 100
Price 54Earnings 68FII/DII 13

Passes these screensCash RichQuality CompounderDebt-light & profitable

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹5,699.5 latest close · −10.2% over the last 90 sessions

₹5,000₹6,000₹7,000Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹5,000₹6,000₹7,000Jul 3Sep 4Nov 9

₹5,699.5 month-end · +2.6% over 12 months

₹5,000₹6,000Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹5,000₹6,000Nov '25May '26Nov '26

₹5,699.5 month-end · +14.5% over 3 years

₹5,000₹6,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹5,000₹6,000Nov '23May '25Nov '26

₹5,699.5 month-end · +77.6% since Jan '19

₹4,000₹6,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹4,000₹6,000Jan '19Dec '22Nov '26

52-week range ₹4707.00 to ₹6975.00 · 1-year volatility 26.4%

Was the rally earned?

+3%share price, 1 yearRoughly flat
  • The share price was roughly flat over 1 year (+3%).
  • The share count barely moved.
Net profit growth: +18 pts. Points of the price return explained by net profit growing (or shrinking).+18 ptsNet profit growthP/E change: −15 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−15 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +3%+3%Share priceNet profit growth: +18 pts. Points of the price return explained by net profit growing (or shrinking).+18ProfitP/E change: −15 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−15P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +3%+3%Share price
Net profit growth+18 ptsNet profit rose about 19%, which lifts the price.
P/E change-15 ptsThe P/E fell from 30.7x to 26.5x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+15%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 47 points, but investors now pay less per rupee of profit (P/E 36.0x to 26.5x), which took 33 points back.
  • The share count barely moved.
Net profit growth: +48 pts. Points of the price return explained by net profit growing (or shrinking).+48 ptsNet profit growthP/E change: −33 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−33 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +15%+15%Share priceNet profit growth: +48 pts. Points of the price return explained by net profit growing (or shrinking).+48ProfitP/E change: −33 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−33P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +15%+15%Share price
Net profit growth+48 ptsNet profit rose about 56%, which lifts the price.
P/E change-33 ptsThe P/E fell from 36.0x to 26.5x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+10%share price, 5 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 74 points, but investors now pay less per rupee of profit (P/E 48.5x to 26.5x), which took 63 points back.
  • The share count barely moved.
Net profit growth: +74 pts. Points of the price return explained by net profit growing (or shrinking).+74 ptsNet profit growthP/E change: −63 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−63 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +10%+10%Share priceNet profit growth: +74 pts. Points of the price return explained by net profit growing (or shrinking).+74ProfitP/E change: −63 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−63P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +10%+10%Share price
Net profit growth+74 ptsNet profit rose about 102%, which lifts the price.
P/E change-63 ptsThe P/E fell from 48.5x to 26.5x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-47.0%not yet recovered
1-year volatility26.4%annualised
Beta vs sector index0.463-year daily, correlation 0.28
Volume spikes4last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%2020202120222023202420252026−46.8% 0%−20%−40%2020202220242026−46.8%
Largest drawdowns

-47.0% (2021-02 peak to 2022-09 low, not yet recovered)

-36.8% (2019-10 peak to 2020-03 low, recovered 2020-08)

-19.1% (2019-05 peak to 2019-05 low, recovered 2019-07)

Most recent volume spikes

2026-11-02: 9.9x the 50-day median, price +2.8% that day

2026-09-29: 10.6x the 50-day median, price +5.5% that day

2026-08-06: 13x the 50-day median, price -6.1% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

26.5xP/E todayNear its historic low
Against its own history16th percentile
CheapestMedian 36.0xDearest

Usual range 9.0x to 44.6x since 2019-01.

Against Health Technology26.5x vs 37.0x
This company
26.5x
Sector median
37.0x

28% below the Health Technology median.

7.1x23.6x40.2x56.7xJan '19Aug '20Mar '22Oct '23May '25Nov '267.1x23.6x40.2x56.7xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE99thflat vs a year ago
  • Op. margin83rdflat vs a year ago
  • Revenue growth54th▼ 4 pts vs a year ago
  • EPS growth65th▼ 21 pts vs a year ago
  • Debt/equity ↓88thflat vs a year ago
  • Cash cycle ↓97thflat vs a year ago
  • P/E ↓68th▲ 15 pts vs a year ago
  • 12M momentum45th▼ 40 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~19%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 40.1x, a holder earning 12%/yr needs earnings to grow about 19.4%/yr for 10 years, then trade at 15x.

Delivered−5.5%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+24.9 ptsimplied minus delivered
Rank87thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

-6%38%83% Jan 2019Nov 2026 -6%38%83% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x20.5%21.5%22.6%
15x18.4%19.4%20.5%
20x15.6%16.6%17.7%

Drag a slider to test other assumptions

Implied: 19.4%/yr

Looking back

  • Jan 2020Price implied 17%/yr; EPS has since grown −12%/yr (7.2 yrs)
  • Jan 2021Price implied 22%/yr; EPS has since grown 5%/yr (5.7 yrs)
  • Jan 2022Price implied 14%/yr; EPS has since grown 14%/yr (4.8 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹5699.50
P/E
26.5x
ROCE
84.0%
Market Cap
₹9462 cr
Revenue (TTM)
₹1433 cr
P/S
6.6x
P/B
18.0x
ROE
68.0%
Operating Margin
27.0%
Debt / Equity
0.0x
Promoter Holding
51.8%
12M Momentum
2.6%

52-week range

₹4707.00₹6975.00
44% of the way from its 52-week low to its high

Price risk

1Y volatility
26.4%
Beta vs sector
1-year daily
0.69

Balance sheet & cash

Debt service
no meaningful debt
Cash from profit, 3Y
operating cash flow ÷ net profit
1.02x
Share count, 1Y
unchanged

Are profits backed by cash?

7 of 7checks within rangeAll clear
Other income reliance10%Within range

Other income as a share of pre-tax profit (trailing twelve months): 10.0%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 26.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.96xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 0.96x (cash from operations ₹735 cr, net profit ₹762 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+9 daysWithin range

Debtor days are above the median of the previous three fiscal years by 9 days (43 vs 34). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress14% of fixed assetsWithin range

Capital work-in-progress is 14% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+8 days / 2 yrsWithin range

Days payable changed by +8 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, FIIs trimmed 1.0 pts.
  • The number of shareholders fell from 57,919 to 49,056 (-15%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters51.8%51.8%0.0 pts
FIIs7.4%6.3%-1.0 pts
DIIs12.3%12.4%+0.1 pts
Public and others28.5%29.4%+0.9 pts

Number of shareholders

49,056shareholders-15% since Sep '23
49k52k55k58k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 57,919
Dec '23: 56,730
Mar '24: 56,778
Jun '24: 55,923
Sep '24: 54,792
Dec '24: 53,736
Mar '25: 53,993
Jun '25: 52,478
Sep '25: 50,006
Dec '25: 49,302
Mar '26: 50,883
Jun '26: 49,056
 49k52k55k58k Sep '23Sep '24Sep '25Jun '26
Sep '23: 57,919
Dec '23: 56,730
Mar '24: 56,778
Jun '24: 55,923
Sep '24: 54,792
Dec '24: 53,736
Mar '25: 53,993
Jun '25: 52,478
Sep '25: 50,006
Dec '25: 49,302
Mar '26: 50,883
Jun '26: 49,056

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−3.9%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like PROCTER AND GAMBLE HEALTH LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −20% to +12% vs the market, against −5% for all non-financial companies in the same months.
  • The gap against the base rate (+1.4%, 80% range −10.0% to +3.1%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
PGHH · Sep 2025: −52.2% vs market
KPITTECH · Oct 2025: −52.0% vs market
BAJAJCON · Apr 2021: −51.7% vs market
SANOFI · Jul 2025: −45.9% vs market
INDIAMART · Oct 2025: −36.1% vs market
IRCTC · Oct 2025: −35.9% vs market
FCL · Jan 2025: −35.2% vs market
SUMICHEM · Jan 2023: −34.3% vs market
CASTROLIND · Jun 2020: −30.3% vs market
DEEPAKNTR · May 2023: −26.4% vs market
IGL · Oct 2020: −26.2% vs market
ACCELYA · Sep 2020: −25.2% vs market
SANOFICONR · Sep 2025: −19.9% vs market
SWARAJENG · Mar 2020: −19.4% vs market
EMAMILTD · Jun 2024: −18.8% vs market
MSUMI · May 2023: −18.6% vs market
AJANTPHARM · Nov 2024: −18.4% vs market
SUPREMEIND · Jun 2021: −18.4% vs market
ALKYLAMINE · May 2025: −17.0% vs market
OFSS · Feb 2020: −14.5% vs market
COHANCE · Jun 2022: −12.5% vs market
PAGEIND · Oct 2025: −11.5% vs market
SKFINDIA · Jun 2023: −11.3% vs market
ACE · Jul 2025: −10.3% vs market
ABBOTINDIA · Oct 2025: −4.4% vs market
CAMS · Mar 2023: −3.4% vs market
SONATSOFTW · Jan 2020: −3.4% vs market
ESABINDIA · Sep 2020: −2.7% vs market
CUMMINSIND · Jul 2024: −2.0% vs market
MPSLTD · Oct 2024: −1.3% vs market
GLAXO · Nov 2024: +1.2% vs market
ECLERX · Mar 2025: +2.7% vs market
EICHERMOT · Apr 2020: +3.1% vs market
3MINDIA · Apr 2025: +3.7% vs market
ATUL · Jan 2021: +10.3% vs market
SHANTIGEAR · Sep 2025: +11.0% vs market
MARICO · Dec 2024: +11.2% vs market
KIMS · Feb 2023: +12.4% vs market
LALPATHLAB · Jun 2025: +17.5% vs market
INGERRAND · Aug 2025: +18.2% vs market
FINEORG · Oct 2025: +20.3% vs market
GILLETTE · Sep 2024: +21.2% vs market
JBCHEPHARM · Feb 2022: +22.1% vs market
CRISIL · Feb 2021: +23.2% vs market
CROMPTON · Jul 2020: +27.4% vs market
CGPOWER · Oct 2023: +29.6% vs market
INOXINDIA · Jul 2025: +54.7% vs market
THYROCARE · Jun 2020: +58.0% vs market
IEX · Feb 2021: +75.3% vs market
LTTS · Nov 2020: +117.2% vs market
Similar setups −3.9%All companies −5.3%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median
−3.9%
All companies' median
−5.3%
Beat the market
40% vs 44%

50 past situations · 50 companies · 36 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
INGERRAND
Producer Manufacturing		 Aug 2025 45x60% −10%−18% +18%
SANOFI
Health Technology		 Jul 2025 32x49% −12%−22% −46%
ABBOTINDIA
Health Technology		 Oct 2025 42x46% 0%−19% −4%
CASTROLIND
Energy Minerals		 Jun 2020 14x91% −5%−21% −30%
SWARAJENG
Producer Manufacturing		 Mar 2020 13x55% −36%−38% −19%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
GILLETTE
Consumer Non-Durables		 Sep 2024 66x59% +38%−7% +21%
ACCELYA
Technology Services		 Sep 2020 16x51% +27%−14% −25%
IRCTC
Consumer Services		 Oct 2025 43x49% −13%−16% −36%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: operating margin, drawdown from 12-month high and 12-month momentum. Not used (unavailable for this company): interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to PROCTER AND GAMBLE HEALTH LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

STYLAM INDUSTRIESSTYLAMIND
Non-Energy Minerals
72%similar
revenuedebt/equity
EMAMIEMAMILTD
Consumer Non-Durables
69%similar
volatilityrevenue growth
GUJARAT PIPAVAV PORTGPPL
Transportation
68%similar
debt/equitymarket cap
INDIAMART INTERMESHINDIAMART
Retail Trade
66%similar
market capvolatility
JYOTHY LABSJYOTHYLAB
Consumer Non-Durables
64%similar
debt/equitymarket cap
SANOFI INDIASANOFI
Health Technology
71%similar
ROCEdebt/equity
AJANTA PHARMAAJANTPHARM
Health Technology
51%similar
volatilityoperating margin
NATCO PHARMANATCOPHARM
Health Technology
51%similar
operating marginEPS growth

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Sep '22

  1. NovPriceVolume reached 9.9x its 50-day median on 2026-11-02; price +2.8% that day.
  2. AugPriceVolume reached 13.0x its 50-day median on 2026-08-06; price -6.1% that day.
  3. JunResultsRevenue (TTM) reached a new high of ₹1,408 cr.
  4. JunPeer rankSlipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
  5. MayPriceVolume reached 37.0x its 50-day median on 2026-05-27; price +10.5% that day.
  6. FebPriceVolume reached 9.0x its 50-day median on 2026-02-09; price +3.7% that day.
  7. SepPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 2nd quartile).
  8. AugPriceVolume reached 29.1x its 50-day median on 2025-08-01; price +5.5% that day.
Show 22 earlier events
  1. JunPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
  2. JunDividendDividend payout cut from 215% to 89% of profit.
  3. MarResultsYear-on-year EPS growth turned positive.
  4. MarPriceVolume reached 7.4x its 50-day median on 2025-03-27; price -5.8% that day.
  5. DecPeer rankMoved into the top quartile of Health Technology on operating margin (from the 2nd quartile).
  6. NovPriceVolume reached 24.3x its 50-day median on 2024-11-05; price +4.9% that day.
  7. SepResultsYear-on-year EPS growth turned negative.
  8. SepPeer rankSlipped to the 2nd quartile of Health Technology on operating margin (from the top quartile).
  9. SepPriceVolume reached 9.7x its 50-day median on 2024-09-11; price +2.1% that day.
  10. JunPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the top quartile).
  11. MayPriceVolume reached 5.0x its 50-day median on 2024-05-08; price -0.1% that day.
  12. JanPriceVolume reached 16.5x its 50-day median on 2024-01-12; price +1.5% that day.
  13. NovPriceVolume reached 10.7x its 50-day median on 2023-11-29; price -0.2% that day.
  14. SepPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 2nd quartile).
  15. AugPriceVolume reached 5.3x its 50-day median on 2023-08-24; price -4.8% that day.
  16. FebPriceVolume reached 32.4x its 50-day median on 2023-02-06; price +14.6% that day.
  17. NovPriceVolume reached 12.6x its 50-day median on 2022-11-30; price +2.5% that day.
  18. SepResultsYear-on-year EPS growth turned positive.
  19. SepPriceFell 47% from the Feb 2021 peak to the Sep 2022 low.
  20. SepPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the bottom quartile).
  21. SepDividendDividend payout cut from 122% to 45% of profit.
  22. SepPriceVolume reached 10.9x its 50-day median on 2022-09-15; price -0.0% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1126.5x₹1433 cr68.0%84.0%0.0x
2026-1026.4x₹1433 cr68.2%84.0%0.0x
2026-0925.9x₹1433 cr68.2%84.0%0.0x
2026-0829.3x₹1408 cr62.5%84.0%0.0x
2026-0733.5x₹1408 cr62.5%84.0%0.0x
2026-0632.1x₹1408 cr62.5%84.0%0.0x
2026-0534.3x₹1349 cr54.7%48.0%0.0x
2026-0429.5x₹1349 cr54.7%48.0%0.0x
2026-0327.1x₹1349 cr54.7%48.0%0.0x
2026-0226.5x₹1285 cr57.2%48.0%0.0x
2026-0127.9x₹1285 cr57.2%48.0%0.0x
2025-1230.0x₹1285 cr57.2%48.0%0.0x
2025-1130.7x₹1273 cr55.9%48.0%0.0x
2025-1033.1x₹1273 cr55.9%48.0%0.0x
2025-0933.8x₹1273 cr55.9%48.0%0.0x
2025-0840.9x₹1218 cr46.7%48.0%0.0x
2025-0737.8x₹1218 cr46.7%48.0%0.0x
2025-0637.7x₹1218 cr46.7%48.0%0.0x
2025-0539.2x₹1159 cr44.0%45.0%0.0x
2025-0434.6x₹1159 cr44.0%45.0%0.0x
2025-0335.1x₹1159 cr44.0%45.0%0.0x
2025-0237.3x₹1159 cr40.4%45.0%0.0x
2025-0139.8x₹1159 cr40.4%45.0%0.0x
2024-1238.8x₹1159 cr40.4%45.0%0.0x
2024-1141.5x₹1151 cr37.5%45.0%0.0x
2024-1042.0x₹1151 cr37.5%45.0%0.0x
2024-0943.5x₹1151 cr37.5%45.0%0.0x
2024-0839.3x₹1168 cr28.6%45.0%0.0x
2024-0739.5x₹1168 cr28.6%45.0%0.0x
2024-0638.0x₹1168 cr28.6%45.0%0.0x
2024-0533.0x₹1230 cr30.5%45.0%0.0x
2024-0434.5x₹1230 cr30.5%45.0%0.0x
2024-0333.1x₹1230 cr30.5%45.0%0.0x
2024-0235.8x₹1230 cr30.5%45.0%0.0x
2024-0136.0x₹1230 cr30.5%45.0%0.0x
2023-1234.7x₹1230 cr30.5%45.0%0.0x
2023-1136.0x₹1230 cr30.5%45.0%0.0x
2023-1035.8x₹1230 cr30.5%45.0%0.0x
2023-0935.9x₹1230 cr30.5%45.0%0.0x
2023-0840.8x₹1114 cr31.3%38.0%0.0x
2023-0745.0x₹1114 cr31.3%38.0%0.0x
2023-0644.0x₹1114 cr31.3%38.0%0.0x
2023-0543.8x₹1114 cr31.3%38.0%0.0x
2023-0439.0x₹1114 cr31.3%38.0%0.0x
2023-0339.2x₹1114 cr31.3%38.0%0.0x
2023-0239.1x₹1114 cr31.3%38.0%0.0x
2023-0134.3x₹1114 cr31.3%38.0%0.0x
2022-1233.1x₹1114 cr31.3%38.0%0.0x
2022-1134.9x₹1114 cr31.3%38.0%0.0x
2022-1033.8x₹1114 cr31.3%38.0%0.0x
2022-0934.4x₹1114 cr31.3%38.0%0.0x
2022-0838.4x₹1009 cr25.1%29.0%0.0x
2022-0740.4x₹1009 cr25.1%29.0%0.0x
2022-0638.2x₹1009 cr25.1%29.0%0.0x
2022-0538.9x₹1009 cr25.1%29.0%0.0x
2022-0440.4x₹1009 cr25.1%29.0%0.0x
2022-0336.5x₹1009 cr25.1%29.0%0.0x
2022-0241.6x₹1009 cr25.1%29.0%0.0x
2022-0146.1x₹1009 cr25.1%29.0%0.0x
2021-1248.7x₹1009 cr25.1%29.0%0.0x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback